Abhoy Sarkar's Avatar
published in Blogs
Feb 24, 2022
Moderna (MRNA, $151.89) beats Q4 earnings expectations

Moderna (MRNA, $151.89) beats Q4 earnings expectations

Moderna  posted fourth quarter earnings that surpassed expectations. The pharma company also boosted its full-year revenue outlook for Covid vaccine sales.

and unveiled a new $3 billion share repurchase plan.

Moderna’s diluted GAAP earnings came in at $11.29 per share for the three months ending in December, beating the Street expectations of $9.90 per share. It  incurred a loss of -69 cents per share loss in the year-ago quarter.  

Revenues of $7.21 billion also exceeded analysts' estimates.

Looking ahead, the company projects sales of its mRNA-1273 coronavirus vaccine, Spikevax , in the region of $19 billion for the year 2022, with additional signed options of approximately $3 billion.

Moderna said that orders have also been confirmed for 2023 from Canada, the United Kingdom and Taiwan.

Related Tickers: MRNA
Related Portfolios: BIOTECHNOLOGY SECTOR